Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24581224 | 0.91 | MAPT (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564693 | 0.86 | LMNA (0.49) | MAPTL3MBTL1HTTHRH3ALDH1A1 | |
| SCHEMBL24564644 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564698 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL29697162 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564561 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564714 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564690 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24564689 | 0.83 | ALDH1A1 (0.45) | MAPTL3MBTL1HRH3ALDH1A1LMNA | |
| SCHEMBL24581205 | 0.82 | LMNA (0.42) | MAPTL3MBTL1HRH3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | MAPT 911/4885L3MBTL1 124/4885KDM4E 3026/4885 |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | HLA-DRB1, CD74, HLA-B | MAPT 3141/4885L3MBTL1 3100/4885KDM4E 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.